To the top

Page Manager: Webmaster
Last update: 9/11/2012 3:13 PM

Tell a friend about this page
Print version

Selective oestrogen recep… - University of Gothenburg, Sweden Till startsida
Sitemap
To content Read more about how we use cookies on gu.se

Selective oestrogen receptor modulators lasofoxifene and bazedoxifene inhibit joint inflammation and osteoporosis in ovariectomised mice with collagen-induced arthritis.

Journal article
Authors Annica Andersson
Angelina I Bernardi
Alexandra Stubelius
Merja Nurkkala Karlsson
Claes Ohlsson
Hans Carlsten
Ulrika Islander
Published in Rheumatology (Oxford, England)
Volume 55
Issue 3
Pages 553-563
ISSN 1462-0332
Publication year 2016
Published at Institute of Medicine, Department of Rheumatology and Inflammation Research
Centre for Bone and Arthritis Research
Institute of Medicine, Department of Internal Medicine and Clinical Nutrition
Pages 553-563
Language en
Links dx.doi.org/10.1093/rheumatology/kev...
Keywords arthritis, selective oestrogen receptor modulators, oestrogen, osteoporosis
Subject categories Basic Medicine, Immunology in the medical area

Abstract

RA predominantly affects post-menopausal women and is strongly associated with development of generalised osteoporosis. To find treatments that target both joint manifestations and osteoporosis in RA is desirable. The third generation of selective oestrogen receptor modulators (SERMs) [lasofoxifene (LAS) and bazedoxifene (BZA)] are new treatment options for post-menopausal osteoporosis. The aim of this study was to investigate the effects of LAS and BZA on arthritic disease and inflammation-associated bone loss using CIA in mice.

Page Manager: Webmaster|Last update: 9/11/2012
Share:

The University of Gothenburg uses cookies to provide you with the best possible user experience. By continuing on this website, you approve of our use of cookies.  What are cookies?